Figure 1.

Mesenchymal stem cells (MSCs) inhibit the proliferation of malignant cells of various hematopoietic origins. (A) The cells (2×10⁴; A20 B lymphoma, FBL3 erythroleukemia and P388 acute lymphocytic leukemia cells) were cultured in the presence or absence of the indicated numbers of MSCs in 96-well plates for 48 h. Cell proliferation was assessed using a Counting kit-8 (CCK-8) assay during the final 4 h of culture. (B) The leukemia and lymphoma cells (2×10⁴) were cultured in 96-well plates in the presence of 2×10⁴ MSCs for the indicated periods of time. (C) A20 cells (2×10⁴) were cultured in 96-well plates. MSCs (2×10⁴) were added directly to the A20 cells or on the other side of a Transwell insert, and the plates were co-cultured for 48 h in the presence or absence of an Akt inhibitor (5 µM). A20 cell proliferation was measured using a CCK-8 assay during the final 4 h of culture. The results are shown as a percentage of cell proliferation in comparison with control lymphoma cell proliferation. Results are expressed as the means ± SD of 3 independent experiments. ^*P<0.05 indicates statistical significance when compared with the control group.